Robert Koblin
Cardiovascular Disease · Beverly Hills, CANPI 1851506083
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 153 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 33 manufacturers, the largest accounting for just 23.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,017 and has fallen 95.2% since, to $49 in 2025.
Across 153 payments — averaging $21.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$783
- Daiichi Sankyo Inc.$343
- Novartis$319
- AstraZeneca$229
- Pfizer$214
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$137
- plus $1K from 27 others
What the payments were for
- Food & beverage$3,303100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 44 | $783 |
| Daiichi Sankyo Inc. | 14 | $343 |
| Novartis | 14 | $319 |
| AstraZeneca | 13 | $229 |
| Pfizer | 11 | $214 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 7 | $137 |
| Biosense Webster, Inc. | 1 | $125 |
| Boston Scientific | 4 | $116 |
| Regeneron Healthcare Solutions, Inc. | 3 | $109 |
| Lilly USA, LLC | 5 | $104 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $77 |
| Biohaven Pharmaceuticals, Inc. | 3 | $74 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $51 |
| Bardy Diagnostics, Inc. | 2 | $50 |
| AbbVie(2 entities) | 2 | $50 |
| Kowa Pharmaceuticals America, Inc. | 1 | $47 |
| Alnylam Pharmaceuticals Inc. | 2 | $47 |
| Heartflow, Inc. | 2 | $44 |
| Merck | 2 | $43 |
| Sanofi-aventis U.S. LLC | 2 | $40 |
| GSK | 2 | $39 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $32 |
| Viiv Healthcare Company | 1 | $29 |
| Eisai Inc. | 1 | $24 |
| Bayer | 1 | $24 |
| E.r. Squibb & Sons, L.L.C. | 1 | $24 |
| Boehringer Ingelheim | 1 | $24 |
| Esperion Therapeutics, Inc. | 1 | $23 |
| Arbor Pharmaceuticals, Inc. | 1 | $18 |
| Genentech USA, Inc. | 1 | $18 |
| Amarin Pharma, Inc. | 1 | $17 |
| Janssen Scientific Affairs, LLC | 1 | $17 |
| Philips North America LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Carto 3$125
How this compares
$3,303 in reported general payments places this provider in the 55th percentile of 2,184 cardiovascular disease providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Repatha SureclickEvolocumab | 16 | $9,339 |
| Olmesartan Medoxomil | 13 | $394 |
| Ezetimibe | 12 | $279 |
| Rosuvastatin Calcium | 14 | $132 |
| Losartan Potassium | 12 | $96 |
| Atorvastatin Calcium | 14 | $36 |
| Allopurinol | 11 | $24 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Beverly Hills
- Bruce SamuelsBeverly Hills$598K
- Charles SwerdlowBeverly Hills$562K
- David FilsoofBeverly Hills$142K
- Ted LoveHillsborough$102.8M
- Paul KurthSanta Barbara$6.1M
- Jason RogersSacramento$4.4M
- Matthew BudoffTorrance$3.6M
- Eric Topolla Jolla$2.2M
- Cathleen Bairey-MerzLos Angeles$1.2M
- Gagan SinghSacramento$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.